A share price of Lineage Cell Therapeutics Inc [LCTX] is currently trading at $1.14, up 2.70%. An important factor to consider is whether the stock is rising or falling in short-term value. The LCTX shares have gain 9.62% over the last week, with a monthly amount glided 32.13%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024. In a post published today on Yahoo Finance, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial and operating results and to provide a business update.
From an analyst’s perspective:
Lineage Cell Therapeutics Inc [AMEX: LCTX] stock has seen the most recent analyst activity on November 02, 2022, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $5. Previously, B. Riley Securities started tracking the stock with Buy rating on June 14, 2022, and set its price target to $4. On August 19, 2021, Noble Capital Markets initiated with a Outperform rating and assigned a price target of $8 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on March 31, 2021.
Lineage Cell Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.84 and $1.57. Lineage Cell Therapeutics Inc [AMEX: LCTX] shares were valued at $1.14 at the most recent close of the market.
Analyzing the LCTX fundamentals
Trailing Twelve Months sales for Lineage Cell Therapeutics Inc [AMEX:LCTX] were 8.77M which represents -58.44% decline. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.85%, Pretax Profit Margin comes in at -2.84%, and Net Profit Margin reading is -2.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.33 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0833 points at the first support level, and at 1.0267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1783, and for the 2nd resistance point, it is at 1.2167.
Lineage Cell Therapeutics Inc [LCTX] reported earnings per share of -$0.04 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.04/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.03 per share as compared to estimates of -$0.04 per share, a difference of $0.01 representing a surprise of 25.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Lineage Cell Therapeutics Inc [AMEX:LCTX] is 2.74. On the other hand, the Quick Ratio is 2.74, and the Cash Ratio is 1.98. Considering the valuation of this stock, the price to sales ratio is 24.50, the price to book ratio is 2.93.
Transactions by insiders
Recent insider trading involved BAILEY DON M, Director, that happened on Feb 08 when 96155.0 shares were purchased. Director, BROADWOOD PARTNERS, L.P. completed a deal on Feb 06 to buy 6.73 million shares. Meanwhile, Director Jayasuriya Anula bought 10000.0 shares on Dec 29.
